ArticleClinical lung cancer2022

Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.

Yizhen Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.